文献速递肝病

粪菌移植治疗肝硬化肝性脑病:THEMATIC试验

Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial.
PubMed 文献 · J Hepatol · 2025-01-10

这项II期随机、安慰剂对照、双盲临床试验在60例接受乳果糖和利福昔明治疗的肝硬化肝性脑病患者中评估胶囊和灌肠粪菌移植的安全性,发现粪菌移植安全且无相关不良事件,事后分析显示接受粪菌移植组肝性脑病复发率低于安慰剂组。

要点

  • 粪菌移植在肝硬化肝性脑病患者中安全,无FMT相关严重不良事件或不良事件报告。
  • 事后分析显示全安慰剂组肝性脑病复发率40% vs 任何FMT组9%,比值比0.15(95%CI 0.04-0.64)。
  • FMT组内肝性脑病复发率在不同给药途径、剂量或供体类型间相似。

核心结论

  • 在已接受最大治疗的肝硬化肝性脑病患者中,粪菌移植安全,无论剂量、途径或供体类型均无FMT相关不良事件报告。
  • 事后分析显示,全安慰剂组肝性脑病复发率最高,且与较低的基线Lachnospiraceae相对丰度和供体定植减少相关。

研究设计与样本

  • II期随机、安慰剂对照、双盲临床试验,纳入60例接受乳果糖和利福昔明治疗的肝硬化肝性脑病患者,每组15例,随机分为四组(3个活性剂量;2个活性+1个安慰剂剂量;1个活性+2个安慰剂剂量;3个安慰剂剂量)。
  • 每位患者接受两粒胶囊和一次灌肠(安慰剂或FMT),随访6个月;FMT来自素食或杂食供体。

主要发现

  • 粪菌移植安全,无FMT相关严重不良事件或不良事件报告;总体严重不良事件(p=0.96)或死亡(p=1.0)组间相似。
  • 肝性脑病复发组间差异显著(p=0.035,Cramer's V=0.39)。
  • 事后分析:全安慰剂组复发率40% vs 任何FMT组9%,比值比0.15(95%CI 0.04-0.64)。
  • FMT组内,肝性脑病复发率在不同给药途径、剂量或供体类型间相似;接受FMT组生活质量改善。
  • 定植在FMT前Lachnospiraceae相对丰度高的患者中最高,在肝性脑病复发者中较低。

关键数值与推荐

  • 主要结局为FMT相关(严重)不良事件/不良事件,采用意向性治疗分析。
  • 次要结局为肝性脑病复发、全因住院、死亡、供体定植和生活质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 肝性脑病复发的组间差异及全安慰剂组与任何FMT组的比较均来自事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Preventing hepatic encephalopathy (HE) recurrence in cirrhosis, which is associated with an altered gut-liver-brain axis, is an unmet need. Benefits of fecal microbiota transplantation (FMT) have been shown in phase I studies, but route and dose-related questions remain. METHODS: We performed a phase II randomized, placebo-controlled, double-blind, clinical trial of capsule and enema FMT in patients with cirrhosis and HE on lactulose and rifaximin. Participants were randomized into four groups (3 active doses; 2 active and 1 placebo dose; 1 active and 2 placebo doses; 3 placebo doses). Each patient received two capsules and one enema (either placebo or FMT) and were followed for 6 months. The primary outcome was FMT-related (serious) adverse events ([s]AEs)/AEs using intention-to-treat analysis. Secondary outcomes were HE recurrence, all-cause hospitalizations, death, donor engraftment, and quality-of-life. FMT was from a vegan or omnivorous donor. RESULTS: We enrolled 60 patients (15/group) with similar baseline characteristics. FMT was safe, with no FMT-related SAEs/AEs reported. Overall SAEs (p = 0.96) or death (p = 1.0) were similar. There were significant differences in HE recurrence between groups (p = 0.035, Cramer's V = 0.39). On post hoc analysis, recurrence was highest in the all-placebo vs. any FMT group (40% vs. 9%; odds ratio 0.15, 95% CI 0.04-0.64). Within the FMT groups, HE recurrence rates were similar regardless of route, doses, or donor type. Quality of life improved in FMT-recipient groups. Engraftment was highest in those with high pre-FMT Lachnospiraceae and lower in those whose HE recurred. CONCLUSIONS: FMT was safe in patients with cirrhosis and HE on maximal therapy, with no FMT-related AEs reported, regardless of dose, route, or donor type. On post hoc analysis, HE recurrence was highest in the placebo-only group and linked with lower baseline Lachnospiraceae and reduced donor engraftment. IMPACT AND IMPLICATIONS: Patients with hepatic encephalopathy (HE) already on maximal therapy could have recurrences, which worsen prognosis and are not prioritized for liver transplant. In this phase II, double-blind, randomized, placebo-controlled trial in patients with cirrhosis and prior overt HE, we found that fecal microbiota transplant (FMT) was safe and well tolerated regardless of route of delivery (oral or enema), number of doses (1 through 3), or donor type (vegan or omnivorous). HE recurrence, which was a key secondary endpoint, was different between groups and, on post hoc analysis, lowest in groups that received any FMT. Donor engraftment was higher in those with higher relative abundance of Lachnospiraceae, which was associated with lower HE recurrence.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Bajaj JS, Fagan A, Gavis EA, et al. Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial. J Hepatol. 2025. PMID: 39800192. doi:10.1016/j.jhep.2024.12.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。